Literature DB >> 18596579

Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry.

Robert J Hopkin1, John Bissler, Maryam Banikazemi, Lorne Clarke, Christine M Eng, Dominique P Germain, Roberta Lemay, Anna Tylki-Szymanska, William R Wilcox.   

Abstract

Fabry disease is an X-linked lysosomal disease caused by deficiency of alpha-galactosidase A. Signs and symptoms of Fabry disease occurring during childhood and adolescence were characterized in 352 Fabry Registry patients. At enrollment (median age 12 year), 77% of males and 51% of females reported symptoms. The median age of symptom onset was 6 year in males and 9 year in females. The most frequent symptom, neuropathic pain, was reported by 59% of males (median age 7 year) and 41% of females (median age 9 year). Gastrointestinal symptoms were reported by 18% of children (median age 5 year in males and 9.5 year in females). Males exhibited height and weight values below the US 50th percentile. Females had weight values above the US 50th percentile. A few patients had serious renal and cardiac manifestations, stage 2 or 3 chronic kidney disease (n = 3), arrhythmia (n = 9), and left ventricular hypertrophy (n = 3). Thus, many pediatric Fabry patients report early symptoms, particularly pain, gastrointestinal symptoms, and impaired quality of life. Some children experience major complications during the pediatric years.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18596579     DOI: 10.1203/PDR.0b013e318183f132

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  79 in total

Review 1.  Lysosomal storage disease overview.

Authors:  Angela Sun
Journal:  Ann Transl Med       Date:  2018-12

2.  Fabry disease in latin america: data from the fabry registry.

Authors:  J Villalobos; J M Politei; A M Martins; G Cabrera; H Amartino; R Lemay; S Ospina; S Suarez Ordoñez; C Varas
Journal:  JIMD Rep       Date:  2012-07-06

3.  Dorsal root ganglia in vivo morphometry and perfusion in female patients with Fabry disease.

Authors:  Tim Godel; Anja Köhn; Nicole Muschol; Moritz Kronlage; Daniel Schwarz; Jennifer Kollmer; Sabine Heiland; Martin Bendszus; Victor-Felix Mautner; Philipp Bäumer
Journal:  J Neurol       Date:  2018-09-12       Impact factor: 4.849

4.  Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry.

Authors:  William R Wilcox; Ulla Feldt-Rasmussen; Ana Maria Martins; Alberto Ortiz; Roberta M Lemay; Ana Jovanovic; Dominique P Germain; Carmen Varas; Katherine Nicholls; Frank Weidemann; Robert J Hopkin
Journal:  JIMD Rep       Date:  2017-05-17

Review 5.  Assessment of renal pathology and dysfunction in children with Fabry disease.

Authors:  Uma Ramaswami; Behzad Najafian; Arrigo Schieppati; Michael Mauer; Daniel G Bichet
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

6.  Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.

Authors:  Raphael Schiffmann; David G Warnock; Maryam Banikazemi; Jan Bultas; Gabor E Linthorst; Seymour Packman; Sven Asger Sorensen; William R Wilcox; Robert J Desnick
Journal:  Nephrol Dial Transplant       Date:  2009-02-13       Impact factor: 5.992

Review 7.  Fabry disease-often seen, rarely diagnosed.

Authors:  Björn Hoffmann; Ertan Mayatepek
Journal:  Dtsch Arztebl Int       Date:  2009-06-26       Impact factor: 5.594

Review 8.  Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring.

Authors:  Björn Hoffmann
Journal:  Orphanet J Rare Dis       Date:  2009-10-11       Impact factor: 4.123

9.  Fabry disease in children and the effects of enzyme replacement treatment.

Authors:  Guillem Pintos-Morell; Michael Beck
Journal:  Eur J Pediatr       Date:  2009-02-26       Impact factor: 3.183

10.  Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.

Authors:  Fernando C Fervenza; Roser Torra; David G Warnock
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.